Lonza Pharma & Biotech and Innosieve Diagnostics announced today an exclusive distribution agreement for rapid bioburden testing technology. This agreement expands Lonza’s extensive offering of ...
Bioburden testing serves a variety of purposes, and the relevance of the data can range from relatively insignificant to extremely critical. Bioburden tests can be used for general tracking or ...
Another driver contributing to the market growth is the growing emphasis on regulatory compliance. Regulatory authorities across the globe are imposing strict guidelines and regulations regarding ...
As biopharma companies fine-tune their strategies for continuous bioprocessing, bioburden control has become a top priority. The approaches that worked for batch processing are inadequate for ...
WILMINGTON, Mass.—October 20, 2014 – Charles River Laboratories International, Inc. (NYSE: CRL) today introduced the PTS-Micro™ system, a new technology platform designed for rapid microbial burden ...
(MENAFN- GlobeNewsWire - Nasdaq) The bioburden testing market is set to grow significantly due to increased demand in pharmaceuticals and medical devices and strict regulatory standards. Key ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results